期刊
ADVANCED DRUG DELIVERY REVIEWS
卷 92, 期 -, 页码 27-38出版社
ELSEVIER SCIENCE BV
DOI: 10.1016/j.addr.2014.12.005
关键词
Sexually transmitted infections (STIs); Microbicides; Preclinical; HIV; HPV; HSV-2; Safety; Efficacy
资金
- United States Agency for International Development (USAID) Cooperative Agreement
Sexually transmitted infections like HIV, HPV, and HSV-2, as well as unplanned pregnancy, take a huge toll on women worldwide. Woman-initiated multipurpose prevention technologies that contain antiviral/antibacterial drugs (microbicides) and a contraceptive to simultaneously target sexually transmitted infections and unplanned pregnancy are being developed to reduce these burdens. This review will consider products that are applied topically to the vagina. Rectally administered topical microbicides in development for receptive anal intercourse are outside the scope of this review. Microbicide and microbicide/contraceptive candidates must be rigorously evaluated in preclinical models of safety and efficacy to ensure that only candidates with favorable risk benefit ratios are advanced into human clinical trials. This review describes the comprehensive set of in vitro, ex vivo, and in vivo models used to evaluate the preclinical safety and antiviral efficacy of microbicide and microbicide/contraceptive candidates. (C) 2014 The Authors. Published by Elsevier B.V.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据